key: cord-0987288-t30yubp6 authors: Trieu, V.; Saund, S.; Rahate, P.; Barge, V.; Nalk, S.; Windlass, H.; Uckun, F. title: Targeting TGF-b pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19 date: 2021-02-01 journal: nan DOI: 10.1101/2021.01.24.21250418 sha: 91bbcd8316a38cb404dfe6e9631c33cc0a886fe9 doc_id: 987288 cord_uid: t30yubp6 Our COVID-19 drug candidate ARTIVeda/PulmoHeal is a novel gelatin capsule formulation of the Artemisia extract Ayurveda for oral delivery of TGF-b targeting anti-malaria phytomedicine Artemisinin with documented anti-inflammatory and anti-SARS-CoV-2 activity. Here we report the safety and efficacy of ARTIVeda in adult COVID-19 patients with symptomatic mild-moderate COVID-19, who were treated in a randomized, open-label Phase IV study in Bangalore, Karnataka, India (Clinical Trials Registry India identifier: CTRI/2020/09/028044). ARTIVeda showed a very favorable safety profile, and the only ARTIVeda-related adverse events were transient mild rash and mild hypertension. Notably, ARTIVeda, when added to the SOC, accelerated the recovery of patients with mild-moderate COVID-19. While all patients were symptomatic at baseline (WHO score = 2-4), 31 of 39 (79.5%) of patients treated with ARTIVeda plus SOC became asymptomatic (WHO score = 1) by the end of the 5-day therapy, including 10 of 10 patients with severe dry cough 7 of 7 patients with severe fever. By comparison, 12 of 21 control patients (57.1%) treated with SOC alone became asymptomatic on day 5 (P=0.028, Fishers exact test). This clinical benefit was particularly evident when the treatment outcomes of hospitalized COVID-19 patients (WHO score = 4) treated with SOC alone versus SOC plus ARTIVeda were compared. The median time to becoming asymptomatic was only 5 days for the SOC plus ARTIVeda group (N=18) but 14 days for the SOC alone group (N=10) (P=0.004, Log-rank test). These data provide clinical proof of concept that targeting the TGF-b pathway with ARTIVeda may contribute to a faster recovery of patients with mild-moderate COVID-19 when administered early in the course of their disease. Effective drugs are needed to prevent the potentially deadly complications of COVID-19 (1) (2) (3) and thereby reduce its fatality rate has become of the main causes of death (4) (5) (6) (7) (8) (9) . Artemisinin is an anti-inflammatory phytomedicine with broad-spectrum antiviral activity and a commonly used anti-malaria drug (10) (11) (12) . Artemisinin and some of its chemical derivatives exhibit broadspectrum antiviral activity against pathogenic human viruses (11, 12) . Notably, recent docking studies indicated that Artemisinin and its derivative Artesunate could bind the SARS-CoV-2 spike protein in a way that would interfere with its docking onto the human ACE2 receptor protein, which is the required first step in the host infection process of the coronavirus disease 2019 (COVID-19) (13, 14) . Studies by Cao et al. (15) and Gilmore et al. confirmed the antiviral activity of Artemisinin and its derivatives against SARS-2-CoV-2 (16) . Its documented anti-SARS-CoV-2 activity has been attributed to its ability to inhibit spike-protein mediated and TGFβ-dependent early steps in the infection process (12) . Table 1 ). There were no significant differences in the baseline characteristics of patients on the experimental versus control arms of the protocol. As of the data cut-off date, safety data were available for all 60 participants, including 39 patients who received ARTIVeda. All AEs encountered in all 60 patients are shown in Table 2 according to their SOC, severity, and relatedness to the assigned treatments. There were no incidences of drug-related deaths or discontinuation of therapy. No treatment-related ≥ Grade 3 AEs were observed in any of the patients. The only ARTIVeda-related AEs were a single occurrence of transient mild rash and mild vertigo ( Table 2) . These AEs did not require additional treatment, and they did not cause discontinuation of the dosing or study. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. Artemisia species contain bioactive substances with pleiotropic biological effects (10, 12) . For example, Artemisia annua contains anti-inflammatory sesquiterpenoids, including Artemisinin (viz.: Artesunate). Artemisinin and its antimalarial properties were discovered by the Chinese scientist Tu Youyu, who became one of the laureates of the 2015 Nobel Prize in Physiology or Medicine for this discovery (12) . Artemisinin and Artemisinin derivatives are generally welltolerated, especially when used for a short treatment course (10, 12, (18) (19) (20) (21) (22) (23) (24) . Except for the rare occurrence of hepatotoxicity and mild-moderate headache, nausea, vomiting, fatigue, and anorexia, Artemisinin was found to be clinically safe in healthy volunteers as well as malaria patients (10, 12, (18) (19) (20) (21) (22) (23) (24) . In the present study, ARTIVeda was administered daily for 5 days as an adjunct to the Remdesivir-based SOC at Site 201, Dexamethasone/Heparin-based SOC at Site 202, or Ivermectin-based SOC at Site 203. No treatment-related ≥ Grade 3 AEs were observed in any of the patients. The only ARTIVeda-related AEs were mild rash and mild hypertension, and these AEs did not require additional treatment, and they did not cause discontinuation of the dosing or study. All AEs considered possibly or probably related to All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. ; ARTIVeda have recovered/resolved with no sequelae. No laboratory abnormalities were observed in the SOC plus ARTIVeda group to suggest drug-related systemic or organ-specific toxicity. Most importantly, no hepatotoxicity was observed in any of the 39 patients treated with ARTIVeda. Artemisinin and some of its chemical derivatives exhibit broad-spectrum antiviral activity against pathogenic human viruses, including SARS-CoV-2 (11, 12) . Artemisinin has also been shown to inhibit the expression of TGF-β mRNA and protein both in vitro and in vivo (25) (26) (27) . Artemisinin treatments mitigated the contribution of upregulated TGF-β expression to the disease pathophysiology in rodent models of diabetic nephropathy as well as lupus nephritis (26, 27) . High-risk COVID-19 patients have a higher probability of developing a potentially lifethreatening multi-system inflammation caused by a cytokine release syndrome (CRS) (4-9). Artemisinin and some of its derivatives are being evaluated as COVID-19 therapeutics (12) . ArtemiC is a medical spray containing Artemisinin, curcumin, Frankincense resin from the Boswellia sacra tree, and Vitamin C. In the controlled Phase II trial NCT04382040, patients with COVID-19 received ArtemiC spray in addition to standard care and preliminary data suggested All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. ; that ArtemiC may be more active than placebo in contributing to the improvement of the patients' condition (50). Likewise, the efficacy signal for the Artemisinin derivative Artesunate during a recently completed prospective, controlled clinical COVID-19 study was promising. In Artesunate treatment group, time to significant improvement of the symptoms, time to conversion to the negativity of SARS-CoV-2 tests, and length of hospital stay was shorter than in the control group (51). Additional data sets are expected from several ongoing active clinical trials designed to evaluate the efficacy of Artemisinin and its derivatives in COVID-19 patients, including NCT04387240 Phase 2 trial testing the efficacy of Artesunate and Artemisinin will be (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. ; Funding/Support. This study was funded by Oncotelic, Inc., a wholly-owned subsidiary of Mateon Therapeutics. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. https://pubmed.ncbi.nlm.nih.gov/32527344/ All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. ; 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2.6) 0 (0) 1 (2.6) 0 (0) 0 (0) Investigations 6 (28.6) 0 (0) 6 (28.6) 0 (0) 0 (0) 4 (10.2) 0 (0) 4 (10.2) 0 (0) 0 (0) Blood pressure increased 2 (9.5) 0 (0) 2 (9.5) 0 (0) 0 (0) 2 (5.1) 0 (0) 2 (5.1) 0 (0) 0 (0) Heart rate increased 4 (19.1) 0 (0) 4 (19.1) 0 (0) 0 (0) 2 (5.1) 0 (0) 2 (5.1) 0 (0) 0 (0) Nervous system disorders 1 (4.8) 0 (0) 1 (4.8) 0 (0) 0 (0) 0 (0) 1 (2.6) 1 (2.6) 0 (0) 0 (0) Vertigo 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2.6) 1 (2.6) 0 (0) 0 (0) Headache 1 (4.8) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Respiratory disorders 1 (4.8) 0 (0) 1 (4.8) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Dyspnea 1 (4.8) Subjects reporting individual adverse events may not add up to the number of subjects within a System Organ Classification (SOC) because a subject may have reported more than one adverse event within an SOC term. For subjects reporting an adverse event with more than one severity assessment under the same MedDRA preferred term (PT), the highest severity is reported. System Organ Class (SOC) and preferred terms within each SOC were sorted alphabetically. The following COVID-19-related presenting signs and symptoms were not included as AEs in this table: Diarrhea, loss of taste/smell, cough, sore throat, conjunctivitis. Each of these have resolved in patients receiving ARTIVeda within 5 days. 2=symptomatic, independent; 3=symptomatic requiring assistance; 4=hospitalized, not requiring oxygen therapy. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. ; https://doi.org/10.1101/2021.01.24.21250418 doi: medRxiv preprint Depicted are the recovery curves showing the time to becoming asymptomatic for the SOC alone and SOC plus ARTIVeda groups along with the log-rank P-value for the comparison. n. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 1, 2021. ; COVID-19 as the Leading Cause of Death in the United States Excess deaths from COVID-19 and other causes All-Cause Excess Mortality and COVID-19-Related Mortality Among US Adults Aged 25-44 Years Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Clinical course and risk factors for mortality of adult inpatients with Risk factors of critical and mortal COVID-19 cases: A systematic literature review and meta-analysis Prognostic Factors Associated with High-Risk for Fatal ARDS in COVID-19 and Potential Role for Precision Medicines as Part of COVID-19 Supportive Care Algorithms Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi-Organ Failure Artemisinin-Based and Other Antimalarials: Detailed Account of Studies by Chinese Scientists Who Discovered and Developed Them The Use Of Antimalarial Drugs Against Viral Infection Microorganisms Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 In-silico Studies of Antimalarial-agent Artemisinin and Derivatives Portray More Potent Binding to Lys353 and Lys31-Binding Hotspots of SARS-CoV-2 Spike Protein than Hydroxychloroquine: Potential Repurposing of Artenimol for COVID-19 Anti-SARS-CoV-2 Potential of Artemisinins In Vitro In vitro efficacy of Artemisinin-based treatments against SARS-CoV-2. bioRxiv Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial The pharmacokinetics of a single dose of artemisinin in healthy Vietnamese subjects Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study The pharmacokinetics of a single dose of artemisinin in patients with uncomplicated falciparum malaria Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens Efficacy and Safety of Artemisinin-Piperaquine for the Treatment of Uncomplicated Malaria: A Systematic Review Artemisinin enhances the anti-tumor immune response in 4T1 breast cancer cells in vitro and in vivo Artemisinin attenuates early renal damage on diabetic nephropathy rats through suppressing TGF-β1 regulator and activating the Nrf2 signaling pathway Therapeutic effect of artemisinin on lupus nephritis mice and its mechanisms Potential approach for fighting against corona virus disease